Business Standard

Glenmark Pharmaceuticals Share Price

Know More
BSENSE

1,025.15-18.55 (-1.78%)

12:00 AM,19th Apr 2024

1,026.40-15.40 (-1.48%)

12:00 AM,19th Apr 2024

BSE : 532296

NSE : GLENMARK

Sector : Health care

ISIN Code : INE935A01035

  • BSE
  • NSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: 19-Apr-2024 | 12:00 AM IST

Market Cap (₹ Cr)

28,930

Turnover (₹ Cr)

0.22

Volume (Shares)

21,850

Face Value

1

52-WK High

1,068.00

52-WK High Date

12-Apr-2024

52-WK Low

507.65

52-WK Low Date

24-Apr-2023

All Time High

1,261.95

All Time High Date

21-Aug-2015

All Time Low

1.89

All Time Low Date

10-Feb-2000

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd was incorporated in November 18th 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is engaged in the business of development manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology Respiratory and Dermatology. Its branded generics business has a significant presence in markets across emerging economies including India. The company has 14 manufact...
Read More

Glenmark Pharma. Announcement

<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>GLENMARK PHARMACEUTICALS LTD.</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24299MH1977PLC019982</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2023-2024</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2021-22 2022-23</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2021-22 2022-23</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Harish Kuber</td></tr><tr><td>Designation :-</td><td>Company Secretary and Compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>V S Mani</td></tr> <tr><td>Designation : -</td><td>Executive Director and Global Chief Financial Officer</td></tr></table><div> <br/> Date: 12/04/2024<br/><br/></div>

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>GLENMARK PHARMACEUTICALS LTD.</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24299MH1977PLC019982</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>AA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>CRISIL LTD.</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>NSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Harish Kuber <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: complianceofficer@glenmarkpharma.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: V S Mani <br/> Designation: Executive Director and Global Chief Financial Officer <br/> EmailId: complianceofficer@glenmarkpharma.com</div> </div> <div> <br/> Date: 12/04/2024<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

View More

Glenmark Pharmaceuticals Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

28,965

EPS - TTM (₹) [S]

37.29

P/E Ratio (X) [S]

1.58

Face Value (₹) 1
Latest Dividend (%)250.00
Latest Dividend Date 18-Sep-2023
Dividend Yield (%) 0.24
Book Value Share (₹) [S]651.23
P/B Ratio (₹) [S]1.58

Funds Owing this Stock

Scheme Name Amount Invested (₹ Cr) No Of Shares Net Asset (%)
HDFC Mid-Cap Opportunities Fund (G) 544.17 56,77,600 0.90
HDFC Mid-Cap Opportunities Fund (IDCW) 544.17 56,77,600 0.90
HDFC Mid-Cap Opportunities Fund - Direct (IDCW) 544.17 56,77,600 0.90
HDFC Mid-Cap Opportunities Fund - Direct (G) 544.17 56,77,600 0.90
Aditya Birla SL Flexi Cap Fund (G) 311.40 32,49,011 1.56
Aditya Birla SL Flexi Cap Fund (IDCW) 311.40 32,49,011 1.56
Aditya Birla SL Flexi Cap Fund - Direct (IDCW) 311.40 32,49,011 1.56
Aditya Birla SL Flexi Cap Fund - Direct (G) 311.40 32,49,011 1.56
ICICI Pru India Opportunities Fund (G) 184.53 19,25,264 1.03
ICICI Pru India Opportunities Fund (IDCW) 184.53 19,25,264 1.03

Load more

Research Reports

Date Broker Action Prices(₹) Report
22-Nov-2022Prabhudas Lilladher Accumulate 410

Stock Strength

Today's Low/High

1,020.15

1,039.45

Week Low/High

1,020.15

1,070.00

Month Low/High

908.35

1,070.00

Year Low/High

507.40

1,070.00

All time Low/High

1.89

1,263.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-2.39%-2.41%-1.56-1.65%
1 Month11.63%11.49%1.491.51%
3 Month16.74%16.75%1.962.43%
6 Month29.52%29.41%11.3712.85%
1 Year100.45%100.47%22.7025.70%
3 Year77.29%77.30%52.4354.23%

Company Info

Company Information

Chairman / Executive Director : Glenn Saldanha

Executive Director (Corporate) : Cheryl Pinto

Executive Director & Group CFO : V S Mani

Non Executive Director : B E Saldanha

Independent Non Exe. Director : Rajesh Desai.

Independent Non Exe. Director : Devendra Raj Mehta

Independent Non Exe. Director : Bernard Munos

Independent Non Exe. Director : Brian W Tempest

Independent Non Exe. Director : Sridhar Gorthi

Independent Non Exe. Director : Sona Saira Ramasastry

Independent Non Exe. Director : Dipankar Bhattacharjee

Independent Non Exe. Director : V R Iyer

Registered Office: B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road,Mumbai,Maharashtra-400026 Ph: 91-22-40189999

Email:complianceofficer@glenmarkpharma.com

URL:http://www.glenmarkpharma.com